LIXTE Biotechnology Mourns the Loss of Founder and Executive Chairman, John S. Kovach
LIXTE Biotechnology Holdings, a clinical-stage biotechnology company specializing in cancer therapy, is deeply saddened to announce the passing of its founder and Executive Chairman, John S. Kovach, M.D. Dr. Kovach, a distinguished medical and scientific professional, dedicated his career to advancing cancer research and treatment. He founded LIXTE in 2005 and served as the Company’s President and Chief Executive Officer until September 2023.
Dr. Kovach’s contributions to the field of oncology were significant. Prior to establishing LIXTE, he held esteemed positions at renowned institutions such as the City of Hope National Medical Center and the Mayo Clinic. Dr. Kovach’s expertise and leadership were instrumental in the development of the Mayo Comprehensive Cancer Center and the Long Island Cancer Center at Stony Brook University Medical School.
Bas van der Baan, who succeeded Dr. Kovach as President and Chief Executive Officer, expressed the profound loss felt by the entire LIXTE team. He acknowledged Dr. Kovach’s wisdom, passion, and the lasting impact he made on the company. Van der Baan assured that LIXTE would continue its mission of improving medical outcomes for cancer patients undergoing various chemotherapies and immunotherapies.
Dr. Kovach’s academic achievements were equally remarkable. He earned a B.A. from Princeton University and an M.D. from the College of Physicians & Surgeons, Columbia University. Throughout his career, he authored over 100 articles on cancer treatment effectiveness, pharmacology, toxicity, and breast cancer epidemiology.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on developing a novel class of cancer therapy called PP2A inhibitors. Their innovative approach aims to enhance the efficacy of chemotherapy and immunotherapy, potentially offering new treatment options for patients. At the heart of their therapy is LB-100, a proprietary compound that acts as an inhibitor of the PP2A phosphatase. LB-100 has shown promising results in promoting the production of neoantigens and cytokines, boosting T-cell proliferation, and disrupting DNA repair mechanisms in cancer cells.
LIXTE is currently conducting multiple clinical trials for solid tumors with unmet medical needs. Their unique approach, backed by a comprehensive patent portfolio, sets them apart from competitors in the field.
The loss of Dr. Kovach is a significant blow to the medical and scientific community. His legacy will undoubtedly continue to inspire advancements in cancer research and treatment. LIXTE Biotechnology remains committed to carrying forward his vision and making a positive impact on the lives of cancer patients.
For more information about LIXTE Biotechnology Holdings, please visit www.lixte.com or contact info@lixte.com. Investors can reach out to PondelWilkinson Inc. Investor Relations at pwinvestor@pondel.com or call (888) 289-5533.
Contact:
LIXTE Biotechnology Holdings, Inc.
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
PondelWilkinson Inc. Investor Relations
Roger Pondel or Laurie Berman: (310) 279-5980